Jinxin Che

1.5k total citations
80 papers, 966 citations indexed

About

Jinxin Che is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Jinxin Che has authored 80 papers receiving a total of 966 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Molecular Biology, 34 papers in Oncology and 12 papers in Hematology. Recurrent topics in Jinxin Che's work include Protein Degradation and Inhibitors (25 papers), Ubiquitin and proteasome pathways (15 papers) and Computational Drug Discovery Methods (11 papers). Jinxin Che is often cited by papers focused on Protein Degradation and Inhibitors (25 papers), Ubiquitin and proteasome pathways (15 papers) and Computational Drug Discovery Methods (11 papers). Jinxin Che collaborates with scholars based in China, Czechia and Macao. Jinxin Che's co-authors include Xiaowu Dong, Yongzhou Hu, Xin‐Yuan Liu, Yuxin Zhuang, Chi‐Ming Che, Tao Liu, Binhui Chen, Yong Yang, Qiaojun He and Liang Gao and has published in prestigious journals such as Nucleic Acids Research, Advanced Materials and Chemical Communications.

In The Last Decade

Jinxin Che

73 papers receiving 953 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jinxin Che China 19 484 199 158 151 142 80 966
Hongqi Tian China 21 485 1.0× 249 1.3× 244 1.5× 219 1.5× 606 4.3× 52 1.5k
Jenny Viklund Sweden 12 416 0.9× 144 0.7× 52 0.3× 38 0.3× 132 0.9× 15 724
Haikuo Ma China 18 343 0.7× 160 0.8× 88 0.6× 137 0.9× 136 1.0× 38 689
Ceyda Açılan Türkiye 20 389 0.8× 391 2.0× 136 0.9× 69 0.5× 242 1.7× 46 941
Wenjing Wang China 15 927 1.9× 350 1.8× 30 0.2× 139 0.9× 247 1.7× 29 1.6k
Michelle L. Turski United States 11 645 1.3× 399 2.0× 40 0.3× 130 0.9× 56 0.4× 20 1.6k
Jason P. Burke United States 9 698 1.4× 167 0.8× 40 0.3× 94 0.6× 282 2.0× 13 950
Kushtrim Kryeziu Austria 15 344 0.7× 412 2.1× 46 0.3× 67 0.4× 185 1.3× 25 846
Sara M. Schmitt United States 14 1.0k 2.1× 834 4.2× 128 0.8× 120 0.8× 451 3.2× 20 1.9k
Tao Meng China 22 439 0.9× 102 0.5× 46 0.3× 119 0.8× 444 3.1× 73 1.3k

Countries citing papers authored by Jinxin Che

Since Specialization
Citations

This map shows the geographic impact of Jinxin Che's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jinxin Che with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jinxin Che more than expected).

Fields of papers citing papers by Jinxin Che

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jinxin Che. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jinxin Che. The network helps show where Jinxin Che may publish in the future.

Co-authorship network of co-authors of Jinxin Che

This figure shows the co-authorship network connecting the top 25 collaborators of Jinxin Che. A scholar is included among the top collaborators of Jinxin Che based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jinxin Che. Jinxin Che is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gao, Lixin, Xiao-Li Zheng, Yu Cao, et al.. (2025). Development of novel epoxyketone macrocyclic peptidyl proteasome inhibitors through OPA-mediated one-step cyclization of unprotected peptides. Bioorganic Chemistry. 156. 108180–108180.
2.
Guo, Yu, Jinxin Che, & Xiaowu Dong. (2025). TransTACs: Transforming antibodies into targeted protein degraders. Acta Pharmaceutica Sinica B. 15(2). 1186–1188. 1 indexed citations
3.
4.
Che, Jinxin, et al.. (2025). Recent Advances in Peptide Linkers for Antibody-Drug Conjugates. Journal of Medicinal Chemistry. 68(19). 19871–19892. 3 indexed citations
5.
Lu, Yang, Peipei Wang, Haifeng Chen, et al.. (2024). Discovery of potent small molecule ubiquitin-specific protease 10 inhibitors with anti-hepatocellular carcinoma activity through regulating YAP expression. European Journal of Medicinal Chemistry. 272. 116468–116468. 9 indexed citations
6.
Wu, Mingfei, Wei Wang, Tao Liu, et al.. (2024). Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML. European Journal of Medicinal Chemistry. 275. 116539–116539. 5 indexed citations
7.
Pan, Youlu, Peipei Wang, Jinxin Che, et al.. (2024). Discovery of N-Benzylpiperidinol derivatives as USP7 inhibitors against Hematology. Bioorganic Chemistry. 153. 107807–107807.
8.
Yu, Qian, Mengna Li, Lixin Gao, et al.. (2024). DiPTAC: A degradation platform via directly targeting proteasome. Acta Pharmaceutica Sinica B. 15(1). 661–664. 2 indexed citations
9.
Yang, Lu, Yaping Xu, Yuxin Zhuang, et al.. (2024). Discovery of New Phenyltetrazolium Derivatives as Ferroptosis Inhibitors for Treating Ischemic Stroke: An Example Development from Free Radical Scavengers. Journal of Medicinal Chemistry. 67(14). 11712–11731. 7 indexed citations
10.
Gao, Jian, et al.. (2024). EvaluationMaster: A GUI Tool for Structure-Based Virtual Screening Evaluation Analysis and Decision-Making Support. Journal of Chemical Information and Modeling. 65(1). 7–14. 2 indexed citations
11.
Yao, Yuejun, Mingfei Wu, Yanfang Wang, et al.. (2024). An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti‐Solid Tumor Immunity. Advanced Materials. 37(3). e2411454–e2411454. 5 indexed citations
12.
Wu, Mingfei, Yanhong Wang, Jingyu Zhang, et al.. (2023). Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer. Bioorganic Chemistry. 142. 106952–106952. 14 indexed citations
13.
Zhong, Yigang, et al.. (2023). A Microenvironment-responsive small-molecule probe and application in quick acute myocardial infarction imaging. Talanta. 270. 125571–125571. 3 indexed citations
14.
Sun, Xiuna, Zhen Chen, Yi Song, et al.. (2023). ADCdb: the database of antibody–drug conjugates. Nucleic Acids Research. 52(D1). D1097–D1109. 41 indexed citations
15.
Lu, Jialiang, Yang Lu, Jian Wu, et al.. (2023). TransFoxMol: predicting molecular property with focused attention. Briefings in Bioinformatics. 24(5). 25 indexed citations
16.
Che, Jinxin, Dan Li, Yu Guo, et al.. (2022). Discovery of new macrophage M2 polarization modulators as multiple sclerosis treatment agents that enable the inflammation microenvironment remodeling. European Journal of Medicinal Chemistry. 243. 114732–114732. 8 indexed citations
17.
Wang, Qianqian, Jinguo Liu, Yu Guo, et al.. (2022). Log P analyzation-based discovery of GSH activated biotin-tagged fluorescence probe for selective colorectal cancer imaging. European Journal of Medicinal Chemistry. 239. 114555–114555. 6 indexed citations
18.
Tian, Tian, et al.. (2020). Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities. Mini-Reviews in Medicinal Chemistry. 21(9). 1113–1122. 1 indexed citations
19.
Lu, Yang, et al.. (2020). Development of differentiation modulators and targeted agents for treating neuroblastoma. European Journal of Medicinal Chemistry. 207. 112818–112818. 15 indexed citations
20.
Che, Jinxin, Rui Song, Binhui Chen, & Xiaowu Dong. (2019). Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead. European Journal of Medicinal Chemistry. 185. 111853–111853. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hongqi Tian Breakdown of academic impact, for papers by Jenny Viklund Breakdown of academic impact, for papers by Haikuo Ma Breakdown of academic impact, for papers by Ceyda Açılan Breakdown of academic impact, for papers by Wenjing Wang Breakdown of academic impact, for papers by Michelle L. Turski Breakdown of academic impact, for papers by Jason P. Burke Breakdown of academic impact, for papers by Kushtrim Kryeziu Breakdown of academic impact, for papers by Sara M. Schmitt Breakdown of academic impact, for papers by Tao Meng
Rankless by CCL
2026